Connective Tissue Diseases and Lung Manifestations

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorMedical University Innsbruck

About this trial

Despite a number of prospective studies already initiated in the past years, the current epidemiology and course of interstitial lung disease (ILD) and pulmonary hypertension (PH) in patients with connective tissue disease (CTD) is still not well defined, particularly regarding its prevalence, incidence and the management of a broad spectrum of disease presentations.

Major challenges include the identification of patients with progressive disease, the appropriate time point of therapeutic intervention and the underlying driver of disease (inflammatory or pro-fibrotic stimulus or both?).

To address these issues in Western Austria, a progressive registry of patients with CTD exploring routine clinical and pathophysiological characteristics of ILD and PH will be conducted. This multidisciplinary, prospective and observational registry aims to collect comprehensive clinical data on incidence, prevalence and course of disease regarding all PH and ILD presentations in a real-world setting.

Eligibility criteria

Qualifiers

The inclusion criteria are adult patients (≥18 years) diagnosed with CTD with signed informed consent.

Disqualifiers

Exclusion criteria are patients with a serious co-morbidity interfering with the course of interstitial lung disease or pulmonary hypertension.

Trial design

Treatments tested in this trial

  • Pulmonary function test
  • Imaging
  • Blood sampling

Treatment groups

No treatment groups listed

Sponsors and collaborators

Medical University Innsbruck

Lead sponsor

Boehringer Ingelheim

Collaborator